Orion Portfolio Solutions LLC Sells 14,132 Shares of Hologic, Inc. (NASDAQ:HOLX)

Orion Portfolio Solutions LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 21.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 51,680 shares of the medical equipment provider's stock after selling 14,132 shares during the period. Orion Portfolio Solutions LLC's holdings in Hologic were worth $3,726,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. General Partner Inc. purchased a new stake in Hologic in the 4th quarter worth about $26,000. Groupama Asset Managment grew its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Raymond James reaffirmed an "outperform" rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They set a "peer perform" rating for the company. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Stephens reiterated an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Price Performance

NASDAQ:HOLX traded up $0.78 during mid-day trading on Thursday, hitting $61.34. The company's stock had a trading volume of 1,486,270 shares, compared to its average volume of 1,810,594. The stock has a fifty day moving average of $64.69 and a 200-day moving average of $72.88. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a fifty-two week low of $58.38 and a fifty-two week high of $84.67. The company has a market capitalization of $13.76 billion, a price-to-earnings ratio of 19.24, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.